文献速递妇科

辅助化疗与早期黏液性卵巢癌患者生存获益无关

Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
PubMed 文献 · Gynecol Oncol · 2019-05-31

该研究基于美国国家癌症数据库2004至2015年诊断的4811例I期黏液性卵巢癌患者,分析辅助化疗与总生存的关系。结果显示30.9%患者接受化疗,化疗组与非化疗组总生存无显著差异(P=0.17),多因素分析中化疗与更好生存无关(HR=1.18,95%CI 0.85-1.64)。

要点

  • I期黏液性卵巢癌患者中30.9%接受了辅助化疗
  • 化疗组与非化疗组5年总生存率分别为86.8%和89.7%,无显著差异(P=0.17)
  • 多因素分析显示化疗与更好生存无关(HR=1.18,95%CI 0.85-1.64)

核心结论

  • 在I期黏液性卵巢癌大样本队列中,接受化疗与生存获益无关。

研究设计与样本

  • 基于美国国家癌症数据库2004至2015年诊断的I期黏液性卵巢癌患者,排除有其他原发肿瘤史者,共纳入4811例,中位诊断年龄51岁(IQR 21)。

主要发现

  • 1488例(30.9%)接受化疗,其中IA/IB期占20.2%,IC期占60.2%(P<0.001)。
  • 化疗组(n=1322)与非化疗组(n=2920)总生存无差异(P=0.17),5年总生存率分别为86.8%和89.7%。
  • 按亚期分层后仍无差异(IA/IB期P=0.46,IC期P=0.11)。
  • 控制亚期、年龄、保险类型、肿瘤分级、淋巴结清扫及合并症后,化疗与更好生存无关(HR=1.18,95%CI 0.85-1.64)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Primary mucinous ovarian carcinoma (MOC) is a rare histologic subtype of ovarian cancer. The benefit of adjuvant chemotherapy for patients with MOC is unclear. PATIENTS AND METHODS: Patients diagnosed with stage I mucinous ovarian cancer (MOC) between 2004 and 2015 were identified from the U.S National Cancer Database. Those with a history of another primary tumor were excluded. Factors independently associated with the receipt of chemotherapy were identified using logistic regression. Impact of chemotherapy on overall survival (OS) for patients diagnosed between 2004 and 2014 was assessed using was Kaplan-Meier curves, and compared with the log-rank test. A multivariate Cox analysis was performed to control for confounders. RESULTS: We identified 4811 patients with a median age at diagnosis of 51 years (IQR: 21). Chemotherapy was administered to 1488 (30.9%) patients; 20.2% and 60.2% for those with stage IA/IB and IC respectively, p < 0.001. Stage IC, larger tumor size, and high tumor grade, were associated with the receipt of chemotherapy. There was no difference in OS between patients who did (n = 1322) and did not (n = 2920) receive chemotherapy, p = 0.17; 5-year OS rate was 86.8% vs 89.7%, respectively. No difference was noted following stratification by substage (p = 0.46 for IA/IB and p = 0.11 for IC). After controlling for substage, patient age, type of insurance, tumor grade, performance of lymphadenectomy and the presence of co-morbidities, the administration of chemotherapy was not associated with better survival (HR:1.18, 95% CI: 0.85, 1.64). CONCLUSIONS: In a large cohort of patients with stage I MOC, receiving chemotherapy was not associated with a survival benefit.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nasioudis D, Haggerty AF, Giuntoli RL, et al. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma. Gynecol Oncol. 2019. PMID: 31155308. doi:10.1016/j.ygyno.2019.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。